Various types of cell-based therapies may hold promise for treatment of potentially severe autoimmune neurological diseases, including neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). This evidence concerns the gene OMG and neuromyelitis optica.